Your browser doesn't support javascript.
loading
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.
Paciullo, Francesco; Bury, Loredana; Noris, Patrizia; Falcinelli, Emanuela; Melazzini, Federica; Orsini, Sara; Zaninetti, Carlo; Abdul-Kadir, Rezan; Obeng-Tuudah, Deborah; Heller, Paula G; Glembotsky, Ana C; Fabris, Fabrizio; Rivera, Jose; Lozano, Maria Luisa; Butta, Nora; Favier, Remi; Cid, Ana Rosa; Fouassier, Marc; Podda, Gian Marco; Santoro, Cristina; Grandone, Elvira; Henskens, Yvonne; Nurden, Paquita; Zieger, Barbara; Cuker, Adam; Devreese, Katrien; Tosetto, Alberto; De Candia, Erica; Dupuis, Arnaud; Miyazaki, Koji; Othman, Maha; Gresele, Paolo.
Afiliação
  • Paciullo F; Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
  • Bury L; Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
  • Noris P; Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Falcinelli E; Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
  • Melazzini F; Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Orsini S; Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
  • Zaninetti C; Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Abdul-Kadir R; PhD program in Experimental Medicine, University of Pavia, Pavia, Italy.
  • Obeng-Tuudah D; Haemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK.
  • Heller PG; Haemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK.
  • Glembotsky AC; Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Fabris F; CONICET, Universidad de Buenos Aires, Instituto de Investigaciones Médicas -IDIM-, Buenos Aires, Argentina.
  • Rivera J; Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Lozano ML; CONICET, Universidad de Buenos Aires, Instituto de Investigaciones Médicas -IDIM-, Buenos Aires, Argentina.
  • Butta N; Clinica Medica 1 - Medicina Interna CLOPD, Dipartimento Assistenziale Integrato di Medicina, Azienda-Ospedale Università di Padova, Dipartimento di Medicina, Università di Padova, Padova, Italy.
  • Favier R; Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
  • Cid AR; Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
  • Fouassier M; Unidad de Hematología, Hospital Universitario La Paz-IDIPaz, Madrid, Spain.
  • Podda GM; Assistance Publique-Hôpitaux de Paris, Armand Trousseau Children's Hospital, French Reference Centre for Inherited Platelet Disorders, Paris, France.
  • Santoro C; Unidad de Hemostasia y Trombosis, Hospital Universitario y Politecnico La Fe, Valencia, Spain.
  • Grandone E; Consultations d'Hémostase - CRTH, CHU de Nantes, Nantes, France.
  • Henskens Y; Medicina III, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
  • Nurden P; Hematology, Department of Translational and Precision Medicine, La Sapienza University of Rome, Rome, Italy.
  • Zieger B; Unità di Ricerca in Aterosclerosi e Trombosi, I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni Rotondo, Foggia, Italy.
  • Cuker A; Ob/Gyn Department of the First I.M. Sechenov Moscow State Medical University, Moscow, The Russian Federation.
  • Devreese K; Hematological Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Tosetto A; Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
  • De Candia E; Division of Pediatric Hematology and Oncology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.
  • Dupuis A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Miyazaki K; Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
  • Othman M; Hematology Department, S. Bortolo Hospital, Vicenza, Italy.
  • Gresele P; Hemostasis and Thrombosis Unit, Insitute of Internal Medicine, Policlinico Agostino Gemelli Foundation, IRCCS, Rome, Italy.
Haematologica ; 105(7): 1948-1956, 2020 07.
Article em En | MEDLINE | ID: mdl-31558677
Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on the current use and safety of thromboprophylaxis, particularly of low-molecular-weight-heparin in these patients is available. Here we explored the approach to thromboprophylaxis and thrombotic outcomes in IPD patients undergoing surgery at VTE-risk participating in the multicenter SPATA study. We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of IPD (VTE-risk: 31% high, 28.6% intermediate, 25.2% low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher prevalence in orthopedic and gynecological surgeries, and was related to VTE-risk. The most frequently employed thromboprophylaxis was mechanical and appeared to be effective, as no patients developed thrombosis, including patients belonging to the highest VTE-risk classes. Low-molecular-weight-heparin use was low (10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic prohemostatic interventions use. Two thromboembolic events were registered, both occurring after high VTE-risk procedures in patients who did not receive thromboprophylaxis (4.7%). Our findings suggest that VTE incidence is low in patients with IPD undergoing surgery at VTE-risk and that it is predicted by the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and low-molecular-weight-heparin should be considered for major surgery.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombose / Tromboembolia Venosa Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombose / Tromboembolia Venosa Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália